Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.